Table 1. Demographic and clinical characteristics of healthy controls and gastric cancer patients.
| Healthy Controls n = 603 | GC patients n = 603 | ORs (95% CI) | P Value | |
|---|---|---|---|---|
| Age yrs ± SD (range) | 70.17 ± 12.32 | 70.32 ± 12.27 | 0.97 | |
| (30–96) | (29–96) | |||
| Gender | 413 M (68.5%) | 413 M (68.5%) | ||
| 190 F (31.5%) | 190 F (31.5%) | 1 (0.78–1.27) | 1.04 | |
| aCigarette smoking | ||||
| Never | 311/585 (53.2%) | 291/582 (50%) | Reference | |
| Former | 184/585 (31.4%) | 162/582 (27.8 %) | 0.94 (0.72–1.23) | 0.68 |
| Current smoker | 90/585 (15.4%) | 129/582 (22.2%) | 1.53 (1.12–2.09) | 0.009 |
| bH. pylori + | 364 (60.4%) | 377/556 (67.8%) | 1.38 (1.09–1.76) | 0.008 |
| CagA+ | 253 (41.9%) | 325/556 (58.4%) | 1.95 (1.54–2.46) | < 0.0001 |
| VacA+ | 237 (39.3%) | 223/556 (40.1%) | 1.03 (0.82–1.31) | 0.81 |
| cFamily history of GC | 33/539 (6.1%) | 88/534 (16.5%) | 3.02 (1.99–4.60) | < 0.0001 |
| Neoplasia location | ||||
| Cardia | 117 (19.4%) | |||
| Non–cardia | 486 (80.6%) | |||
| Lauren's classification | ||||
| Intestinal | 250 (51.4%) | |||
| Diffuse | 178 (36.6%) | |||
| Mixed or undetermined | 58 (11.9%) | |||
| dTNM stage | ||||
| Stage I | 80 (13.3%) | |||
| Stage II | 79 (13.1%) | |||
| Stage III | 131 (21.7%) | |||
| Stage IV | 264 (43.8%) | |||
| Could not be assessed | 49 (8.1%) | |||
| Surgical treatment | 410 (68%) | |||
| Chemotherapy | 225 (37.3%) | |||
| Radiotherapy | 105 (17.4%) |
GC, gastric cancer; n, number of individuals; OR, odds ratio; CI, confidence interval; SD, standard deviation; M, male; F, female.
aInformation was available for 585 HC and 582 GC patients.
bHelicobacter pylori infection and CagA/VacA antibody data obtained by western blot analysis in serum samples. Information was available for 603 HC and 556 GC patients.
cInformation was available for 539 HC and 534 GC patients.
dClinical tumor stages according to the International Union Against Cancer (UICC) criteria. In 49 GC patients tumor stage could not be assessed.